Vitreoretinal Surgery (Retina) — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-26.

Also called: Retina, VR surgery, surgical retina. A 2-year fellowship entered after a full ophthalmology residency, not a residency you match into from medical school, and matched through the SF Match (society-run, non-ACGME) rather than the NRMP. A shorter 1–2 year medical retina route exists for the non-surgical version. Organ system: the retina, vitreous, and macula, the light-sensing back of the eye.

Subspecialty fellowship of Ophthalmology.

The 30-second version

Vitreoretinal surgery is the deep end of the eye, the highest-earning, most surgically demanding, and most call-heavy corner of ophthalmology. Retina specialists manage everything at the back of the eye: they reattach detached retinas, operate inside the eyeball through a microscope with instruments the width of a needle (vitrectomy), and treat the two diseases quietly blinding the developed world, diabetic retinopathy and age-related macular degeneration (AMD), the latter increasingly with a firehose of anti-VEGF injections given right in the clinic. The trade at the center of the field: it pays the most in all of ophthalmology (retina averages roughly $630k–$700k, well above the ~$450–475k comprehensive-ophthalmology figure), and it's intellectually and technically the summit of the specialty, bought with the longest fellowship (2 years), the heaviest urgent call, and the grind of a high-volume injection clinic where you may see 40–60 patients a day. It keeps the ROAD-lifestyle income of ophthalmology while giving up a good chunk of the ROAD lifestyle. One distinction to get straight early: surgical retina (the 2-year fellowship, OR plus clinic) is different from medical retina (a shorter, injection-and-laser, no-vitrectomy path). Same diseases, very different day.123

Quick dashboard (details and sources below)
Training after med school 6 years (1 intern PGY-1 + 3 ophthalmology + 2 yr retina fellowship)
Total from college start ~14 years (4 undergrad + 4 med school + 4 ophthalmology training + 2 fellowship)
Training chain Med school (4) → PGY-1 intern year → 3 yr Ophthalmology → 2 yr Vitreoretinal Surgery fellowship
Competitiveness (as a Vitreoretinal Surgery (Retina) fellowship) High — the most sought-after ophthalmology fellowship; ~123 filled of ~160 offered in 2019, the most recent published counts, but selects for top residents from top programs ⟳
Typical full-time pay ~$630,000–$700,000 total comp (crowdsource/survey) — the highest-earning ophthalmology subspecialty ⟳
Pay vs. general ophthalmology Retina ~$699k, +37% above the $509k ophthalmology-wide average its own source publishes; against comprehensive ophthalmology's ~$450k–$475k the gap is +47–55% 4 ⟳
Lifestyle Keeps ophtho's income but not its calm — heaviest ophtho call + high injection-clinic volume
Burnout Inherits ophthalmology's low baseline (25.8% against a 41.9% all-physician average, AMA 2025) but with a real high-volume/call load stacked on ⟳
% women No clean retina figure — inherit ophthalmology (28% practicing, 42.6% of residents); surgical retina perceived to skew more male ⟳
DO / IMG accessibility Low — gated behind an already DO/IMG-unfriendly residency, then a selective fellowship ⟳

What they actually do

Vitreoretinal specialists own the back of the eye: the retina (the light-sensing tissue), the vitreous (the gel filling the eyeball), and the macula (the central-vision bullseye). They diagnose and treat retinal detachment, diabetic retinopathy (leaking, bleeding, and scarring vessels from diabetes), age-related macular degeneration (wet and dry AMD), retinal vein and artery occlusions, macular holes and puckers (epiretinal membranes), intraocular tumors and trauma, and inherited retinal disease. Two big things dominate the modern job: surgery inside the eye and injections into the eye.12

The signature operation is the pars plana vitrectomy (PPV), in which the surgeon places tiny ports through the white of the eye, removes the vitreous gel, and works directly on the retina under an operating microscope with a wide-angle viewing system: peeling microscopically thin membranes, repairing detachments, clearing blood, and often exchanging fluid for gas or silicone oil to hold the retina in place while it heals.1 Retinal-detachment repair also uses the scleral buckle (a silicone band cinched around the eye) and pneumatic retinopexy (a gas bubble plus laser or cryotherapy done in clinic). The other half of the job, and increasingly the volume driver, is the intravitreal injection: a quick in-office shot of an anti-VEGF drug (aflibercept, ranibizumab, bevacizumab, faricimab, and newer/longer-acting agents) into the eye to treat wet AMD, diabetic macular edema, and vein occlusions. These are given by the hundreds per week in a busy practice; anti-VEGF therapy is the single biggest reason a modern retina clinic runs at 40–60 patients a day.15

The work rewards elite microsurgical skill (operating on tissue microns thick, where a slip blinds), fast, high-stakes decision-making (a fresh macula-threatening detachment is a same-day surgical emergency), and stamina for volume (the injection clinic is a conveyor belt). It is the most procedurally intense ophthalmology subspecialty and the one that most feels like being a surgeon.12

Representative procedures / settings: pars plana vitrectomy (for detachment, diabetic tractional detachment, macular hole, epiretinal membrane, vitreous hemorrhage, dislocated lens/IOL, endophthalmitis) · scleral buckle · pneumatic retinopexy · intravitreal anti-VEGF and steroid injections (the daily-bread procedure) · laser photocoagulation (panretinal for diabetes, focal, barrier laser for tears) · cryotherapy · intraocular tumor and trauma management. Settings: hospital OR and surgeon-owned ambulatory surgery centers (ASCs) for cases, plus a high-throughput office/clinic for exams, imaging (OCT, fluorescein angiography, wide-field photography), lasers, and injections.12

A day in the life (clinic day, 3–4 of these a week): A dense, fast outpatient panel of post-op detachment and vitrectomy checks, diabetic and AMD patients cycling through imaging (OCT is read on nearly everyone), and a steady stream of injections (frequently done in an efficient "injection lane" so the physician moves room to room). Urgent add-ons, a new flashing-lights-and-floaters detachment or a vitreous hemorrhage, get worked in the same day. It is high-volume, pattern-recognition-heavy, and physically repetitive. A surgery day (typically ~1/week) means blocked OR and ASC cases: vitrectomies and buckles, some quick, some (diabetic tractional detachments, complex redos) long and technically brutal. Call: retina carries the heaviest urgent and emergent call in ophthalmology, since retinal detachments, ruptured globes, and endophthalmitis don't wait and a macula-on detachment is an "operate today or tomorrow" problem, but community-practice reality is that most emergencies surface during clinic hours, with true after-6pm surgeries only a handful of times a year and weekend work often just brief post-op checks.31

The training path & time to completion

Medical school (4 yrs) → PGY-1 intern year → 3 years of ophthalmology residency (PGY-2–4) → 2-year Vitreoretinal Surgery (surgical retina) fellowship → practice.16

  • It's a fellowship on top of an already-competitive residency. You must first get into ophthalmology, itself one of the most competitive specialties in medicine, matched through the separate, earlier SF Match with a separate intern year (see the parent ophthalmology profile), and then compete again for retina. So the retina path runs through two selective gates.1
  • Fellowship length: 2 years for surgical retina. This is the longest of the standard ophthalmology fellowships (most others are 1 year). Fellows typically log ~350–500 primary surgical cases in training.27
  • Matched through SF Match, and NON-ACGME. Like almost all ophthalmology fellowships, retina is overseen by the AUPO Fellowship Compliance Committee (FCC) and matched through the SF Match Central Application Service rather than the ACGME and NRMP system. There is no ABMS subspecialty board certificate for retina; you remain board-certified in ophthalmology (American Board of Ophthalmology) and practice retina on the strength of the fellowship. This "non-accredited, no separate board" structure is normal for ophthalmology and surprises people coming from IM/neurology. (ABMS has explored an "Area of Focused Practice" designation in retina, with an application document dated 2024, but there is no standard retina board exam as of 2026.)68 ⟳
  • The medical-vs-surgical fork (multi-entry routes):
  • Surgical retina = the 2-year fellowship above; you operate (vitrectomy, buckle) and run the medical/injection side.
  • Medical retina = a 1–2 year (commonly 1-year) fellowship focused on the medical management of retinal disease: imaging, laser, and injections, but no intraocular surgery. It suits people who want the retinal diseases and the injection/imaging craft without the OR, the long fellowship, or the surgical call. Some comprehensive ophthalmologists also do a subset of medical-retina work without a formal fellowship.23
  • Board: no retina-specific board. Certification is general ophthalmology via the American Board of Ophthalmology (ABO) (Written Qualifying Exam + Oral Exam, 10-year certificate). Retina competence is attested by fellowship completion, not a separate ABMS exam.8
  • Total from the start of college: ~14 years (4 undergrad + 4 med school + 4 ophthalmology training + 2 fellowship). That's the longest common ophthalmology track. Comprehensive ophthalmology is ~12 years, and retina adds the 2-year fellowship.1

How competitive is it? (as a fellowship)

Retina is widely considered the most competitive and most sought-after ophthalmology fellowship, the one that draws the strongest residents from the strongest programs, largely because it combines the top pay, the most surgery, and the greatest intellectual depth in the field.12

The match numbers (SF Match / retina fellowship match): the field runs a persistent surplus of positions over filled spots, but that's misleading, because the unfilled slots reflect programs applicants didn't rank highly rather than a lack of competition for the desirable ones. From the published match-trend analysis: between 2014 and 2019, programs grew from 101 to 119 and filled positions from 118 to 123, while offered positions reached ~160 with 123 filled (i.e., 37 vacancies), so the filled count stayed relatively flat even as slots expanded — the paper's own conclusion.72 ⟳ (Retina fellowship match has no clean annual NRMP-style public table; these are the best hard figures, through 2019, and recent exact counts are limited data.)

Who matches (the honest read): the peer-reviewed match analysis, covering applicants from 2010 to 2017, found the strong independent predictors of matching were graduating from a US residency (~2.1× odds), a top-10-ranked residency (~1.7×), holding an allopathic MD (~2.4× vs other degrees), more completed interviews (~1.3× per interview; matched applicants did a median of ~10), and higher USMLE Step 3 scores. Translation: it selects hard for US-MD graduates of well-regarded programs with research and strong surgical exposure. IMG and DO applicants can and do match, but they face the same headwinds that already make ophthalmology residency tough to reach, compounded a second time.7

The competitive question is whether you can land one of the good ones, not whether there are open seats. There are, and the answer depends on having excelled in a competitive residency. The bottleneck is quality and selectivity at the desirable programs rather than raw supply.72

Board: general ophthalmology (ABO), with no separate retina board.8

Compensation — the robust version

Here's the fact that anchors the field: retina is the highest-earning ophthalmology subspecialty, period. Where the parent profile pegs comprehensive ophthalmology at roughly $450k–$475k typical total comp (owners higher), retina sits meaningfully above it. Read every number below against that comprehensive baseline, because that's the real comparison.

The subspecialty premium. Physician Side Gigs puts retina at ~$699,000 average, about 37% above the ophthalmology-wide average and the top of the subspecialty table.4 SalaryDr's crowdsource (small and owner-heavy, so illustrative of the upper and owner range rather than a population median) reports retina median ~$700,000, average ~$628,000, 25th–75th percentile ~$508k–$740k (n≈12).9 Marit Health lists retina ~$545k average (a lower, broader-sample figure).10 A defensible "typical full-time" read for 2025–26 is ~$550,000–$700,000 total comp, with private-practice owners running higher and employed/academic roles lower. ⟳

Why retina pays more than comprehensive ophthalmology:

  • Procedure and injection volume. Retina stacks high-RVU surgery (vitrectomy, buckle) on top of an enormous injection volume, since anti-VEGF injections are frequent, reimbursed procedures, and a busy retina practice runs 40–60 patients/day with many getting shots. Volume is the engine.51
  • Buy-and-bill drug economics (a real, scrutinized lever). Under Medicare Part B, retina practices often purchase expensive anti-VEGF drugs and bill for them ("buy-and-bill"), earning a percentage-based margin on the drug plus an administration fee. CMS's own expenditure table puts ophthalmology second of all specialties in Medicare Part B payments — $7.35 billion of $118.2 billion in CY2021, behind only internal medicine, a far larger specialty — and two anti-VEGF drugs alone accounted for about 12% of the whole Part B budget on 2015 data.1112 That is a genuine income driver and it is policy-exposed, since biosimilars, drug-pricing reform, and the choice between a cheap compounded bevacizumab and branded agents all move the math. ⟳
  • ASC / ownership upside. Like the rest of ophthalmology, surgeon-owned surgery centers and practice equity add facility-fee income on top of professional fees, the same ownership lever that defines the parent field, amplified by retina's surgical volume.4

Structure and progression (anecdote, from a Student Doctor Network thread whose posts run from 2014 to 2016). Retina surgeons posting there described private-practice starting salaries around $200k–$300k during a partnership track, stepping up substantially at partnership, with partner take-home well into the high six figures. Partnership is framed as earned rather than automatic, since you must generate enough clinical volume, and owners carry the real financial and overhead risk that employees don't. Read it as anecdote rather than survey data, and read the dollar figures against their vintage: they are a decade old and nothing published has refreshed them.39 ⟳

Setting. SalaryDr's 12-physician panel shows private practice ($633k avg) above hospital-employed ($604k); the broader ophthalmology pattern holds, with private practice and ownership well above employed and academic roles, and academic retina, as with academic ophthalmology generally, pays notably less than private practice.94 ⟳

The trend that colors all of it. Retina's economics ride on two things that could both compress: anti-VEGF reimbursement/drug policy (biosimilars and any Part-B pricing reform hit the buy-and-bill margin) and broader ophthalmology reimbursement pressure on high-volume procedures. Demand, though, is structurally rising, since an aging population means more AMD and the diabetes epidemic means more diabetic retinopathy, so the volume side is a tailwind even as per-unit economics face headwinds.5 ⟳

Lifestyle

Retina is the corner of ophthalmology that keeps the income but spends down the lifestyle. Ophthalmology is the "O" in the ROAD (Radiology, Ophthalmology, Anesthesiology, Dermatology) lifestyle group, but retina is the subspecialty where that reputation frays most. You still get an outpatient, mostly-scheduled career with no ward service; what you give up is the calm.13

Hours sit at or above the ophthalmology average (parent field ~46 hrs/week), pushed up by high clinic volume and surgery days. The defining texture is volume: community reports describe 40–60 patient visits a day across ~3–4 clinic days, plus roughly one OR day a week, a genuinely busy schedule, physically repetitive (a lot of injections), and mentally demanding (a lot of OCTs to read and detachments to catch).3

Call is the heaviest in ophthalmology. Retina and oculoplastics carry the specialty's real urgent/emergent burden; among them retina owns the true surgical emergencies: retinal detachment, endophthalmitis (infection inside the eye), open-globe trauma, dropped lens fragments. A macula-threatening detachment is a same-day/next-day operation, so the retina surgeon is the one who gets called. But the community's own reality check is important and reassuring: in most private-practice settings the great majority of "emergencies" actually present during clinic hours and get worked in; genuinely late surgeries (after 6–7pm) happen only a handful of times a year (usually for endophthalmitis), and weekend duty is often just brief post-op checks 1–2 times a month rather than brutal in-house call.3 The lived call burden is heavier than comprehensive ophthalmology but far lighter than general-surgery or EM call, and, as everywhere, it depends enormously on group size and whether call is shared.

The honest counterweight is the grind of volume and repetition rather than grueling nights. The injection clinic is a conveyor belt; the same three or four diseases (AMD, diabetic retinopathy, vein occlusions, detachments) recur constantly; and the mental load of never missing a subtle detachment or a wet-AMD conversion is real. This is a high-throughput surgical life, not a contemplative one.

Lifestyle rating: 3.5/5. Better than most surgical fields (outpatient, mostly elective, no inpatient service, call that's usually manageable in a good group), but a clear step down from comprehensive/cataract ophthalmology's 5/5 because of the longer fellowship, the volume, and the heaviest call in the specialty. As with the parent field, the best version is a well-staffed private/ownership version where call is shared.

Wellbeing — the part to take seriously

Burnout. No clean stand-alone "retina burnout %" exists, so read it through the parent field plus the specialty's known stressors. Ophthalmology has among the lowest burnout in medicine, at 25.8% against a 41.9% all-physician average on the AMA's 2025 Organizational Biopsy, second-lowest of the rows it names.13 Medscape reads the field the same direction on its own scale, 39% against that survey's 49% average, with reported depression roughly half the physician average (~10%).13 Retina inherits that favorable baseline of outpatient work, high autonomy, high income, and visible good outcomes, but stacks on real load: high daily volume, buy-and-bill and reimbursement stress, the heaviest ophthalmology call, and the physical repetition of an injection practice. Net read: still likely below the all-specialty burnout average, but the hardest-working end of a low-burnout field, so don't assume you inherit cataract-surgeon calm. (Cite the parent ophthalmology figures; the retina-specific delta is directional, not measured.) ⟳

Satisfaction is genuinely high, on a very small sample. SalaryDr's retina panel is twelve owner-heavy respondents; they report career satisfaction of 4.7/5, and ten of the twelve say they would choose the field again.91 ⟳ That is reported here as a count rather than the 83% it works out to, because a percentage off twelve people implies a precision the sample cannot carry. Nobody publishes a cross-specialty would-choose-again table — Medscape retired that one around 2019 — so there is no way to say where retina sits against other fields. People cite case variety, real surgical craft, and the drama of saving sight you can watch come back (a detached retina reattached, a bleed cleared) as the payoff.

Emotional load is a real mix:

  • The highs are vivid. Reattaching a retina or clearing a dense vitreous hemorrhage gives immediate, visible, sight-restoring wins, some of the most satisfying acute saves in all of ophthalmology.
  • The lows are chronic and grinding. Much of the panel is progressive, incurable disease you manage rather than cure: advanced diabetic eye disease heading toward blindness despite everything, dry AMD with no good treatment, patients you inject every 4–8 weeks for years. Delivering "we can slow this but not fix it" repeatedly, to the same patients, is its own quiet weight.

Career longevity is a real strength, with an asterisk. Like the rest of ophthalmology, retina is microsurgery you can sustain for decades, with no heavy standing or retracting and no long open cases, and clinic and injection work scales gracefully, retina surgeons commonly practice into their 60s. The asterisk is that vitrectomy demands fine tremor-free control and good stereopsis, so some taper surgical volume with age while keeping the medical and injection side, a natural, built-in off-ramp (much like the medical-retina role) that preserves the career.1

Who's in the field (demographics)

Retina-specific demographic breakdowns are sparse (limited data), so inherit the parent ophthalmology figures and read fellowship signals cautiously.

  • Women: no clean retina-specific figure (limited data). Inherit ophthalmology: 28% of practicing ophthalmologists are women on AAMC's 2022 data, below the ~38% all-specialty average, with a more balanced 42.6% of residents in AY2024-25.14 Surgical retina, like most surgery-heavy subspecialties, is perceived online to skew somewhat more male than the outpatient and medical side, but no reliable retina-specific percentage exists, so this is community perception rather than an asserted fact. ⟳
  • DO: a small minority, gated behind an already DO-unfriendly residency (DO seniors match ophthalmology at ~34%) and then a selective fellowship that favors allopathic MDs (~2.4× odds). No retina-specific DO figure; directionally low.714 ⟳
  • IMG: low, since ophthalmology is one of the least IMG-accessible residencies (IMGs ~2–3% of matched), and the retina match analysis found US-residency graduation the strongest adjusted predictor of matching (~2.08× odds), with holding a US visa favored in the unadjusted comparison of matched against unmatched applicants but not surviving the multivariable model. Retina is therefore among the harder subspecialties for IMGs to reach, not impossible since US-residency-trained IMGs do match, but a steep, two-gate climb.714 ⟳
  • URiM: no retina-specific data (limited data). Parent ophthalmology reported ~15% of matched residents were URiM in 2025; ophthalmology is cited as having below-average URiM representation overall.14 ⟳

Culture, personality & the online stereotypes

Who gravitates here: the ophthalmology residents who wanted the most surgery and the most disease depth, people energized by operating inside the eye, by the intellectual richness of retinal pathology and imaging, and by being the specialist other ophthalmologists refer to. They tend to be technically ambitious, high-endurance, and comfortable with volume, the "gunners" of ophthalmology in the field's own affectionate, needling shorthand. Many are also drawn by the plain fact that it pays the most. As always, plenty of people in the field don't fit any of this.

The stereotypes. Community perception rather than fact. Each carries a kernel and an unfair edge, and plenty of people do not fit the mold:

  • "The top of the ophtho food chain, the gunners." The read online is that retina takes the strongest, most driven residents and is the prestige subspecialty. Kernel of truth (it's the most competitive fellowship and the highest-paid). The unfair edge is that it frames a whole field of hard-working clinicians as status-chasers, which most aren't.
  • "Chose the money and the surgery, gave up the ROAD lifestyle." The perception that retina people traded ophthalmology's famous chill for income and OR time. A real trade-off, but overstated: the call is manageable in most groups and the outpatient life is still far gentler than most surgical fields.
  • "Injection factory." A dig that modern retina has become a high-volume anti-VEGF assembly line: same shot, same diseases, all day. There's a kernel (injection volume is genuinely huge and repetitive), but it undersells the surgery, the imaging/diagnostic craft, and the detachment saves.
  • "Married to the buy-and-bill." A more cynical online take that retina's income is propped up by drug-margin economics that could vanish with policy change. It's a real structural exposure, but it caricatures a field whose core value is genuine sight-saving surgery.

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, the tone is that retina is the pinnacle and the payoff of ophthalmology, with the most surgery, the most money, and the most respect, but that the modern reality is high-volume clinic and injection work, not glamorous all-day operating. Experienced retina docs push back hard on the old "retina ruins your life" reputation: they describe private-practice retina as very reasonable now that technology has shortened surgeries, with most emergencies handled during clinic hours and only occasional late nights. The recurring serious debates are economic: whether the outsized pay is durable given anti-VEGF reimbursement and buy-and-bill exposure, how to spot a fair vs. predatory partnership track (starting salaries in the $200–300k range stepping up at partnership), and the volume grind against the surgical rewards. The medical-against-surgical choice comes up constantly: medical retina for those who want the diseases without the OR, surgical for those who want it all. The overall verdict: proud of the craft and the saves, clear-eyed about the volume and the reimbursement risk, and broadly agreed that it's the most rewarding and most demanding path in the eye.315

Voices from the field. Paraphrased from public writing, with links to the originals:

  • Practicing retina surgeons on the Student Doctor Network repeatedly correct the outdated "retina means no life" stereotype, describing private-practice surgical retina as reasonable (surgeries far faster than a generation ago, most emergencies during clinic hours, rare true late nights), while being candid about the volume, the partnership-track economics, and reimbursement uncertainty as the real concerns.3
  • Eyes On Eyecare's retina-fellowship guides lay out the surgical-against-medical fork plainly (2-year surgical against ~1-year medical), the SF Match process, the ~350–500 surgical cases of training, and injections as the most common in-office procedure, a clear-eyed picture of a demanding but craft-rich fellowship.2
  • Retina Today's "Profile of a Medical Retina Specialist" makes the case for the non-surgical path of retinal diseases, imaging, laser, and injections without the OR or the surgical call, a legitimate, lower-intensity way into the same pathology.16

Why people choose it / why people leave

Why choose it: the highest pay in ophthalmology (~$630–700k vs ~$450–475k comprehensive) · the most surgery and the deepest disease/imaging craft in the specialty · dramatic, visible sight-saving wins (reattaching a retina, clearing a bleed) · rising structural demand (aging → AMD, diabetes epidemic → retinopathy) → strong job security · still an outpatient, mostly-elective, no-ward career with ownership/ASC upside · a built-in later-career off-ramp (taper surgery, keep medical retina).

Why leave or avoid it: the longest ophthalmology fellowship (2 years) on top of an already-long, already-competitive path (~14 years total) · the heaviest call in ophthalmology · a high-volume, repetitive injection-clinic grind (40–60 patients/day) · reimbursement/buy-and-bill exposure that could compress the pay premium · lots of progressive, incurable disease you manage but can't fix · a two-gate selection process (competitive residency, then competitive fellowship) that's hard to reach for DO/IMG applicants.

Best fit if: you want the most surgery and the most money in ophthalmology and will trade calm for it · you have elite fine-motor control and stereopsis and love operating inside the eye · you thrive on volume and fast pattern recognition · you find retinal disease and imaging genuinely fascinating · you can tolerate (or share away) the heaviest ophthalmology call · you're entrepreneurial about practice/ASC ownership.

Not for you if: you chose ophthalmology for the ROAD lifestyle and want the calmest possible version (comprehensive/cataract is that) · you dislike high-volume repetitive procedures · you want mostly-curable, mostly-elective work without emergencies · you'd resent income that leans on drug-margin economics · you don't want to add two more years and a second selection gauntlet.

The FLI angle — Vitreoretinal Surgery (Retina) for first-gen, low-income & immigrant students

Retina is one of medicine's strongest wealth-and-craft plays, the highest-earning ophthalmology subspecialty, with ownership upside and durable demand. But it sits behind two of the hardest gates in medicine, stacked on top of each other, so the FLI calculus is unusually front-loaded.

Where retina fits FLI realities well:

  • Top-tier earning power for building generational wealth. At ~$630–700k typical (owners higher), retina is among the highest-paid fields in all of medicine, with the same ASC/practice-ownership lever that makes ophthalmology a genuine business path, capturing facility and, in retina, drug and injection economics rather than just a salary. For a first-gen physician starting from zero, that's a real ladder to wealth.49
  • Rock-solid demand and geographic flexibility. Aging (AMD) and the diabetes epidemic (retinopathy) guarantee rising volume; retina specialists are needed everywhere, including in underserved and non-coastal markets that pay recruitment premiums, real leverage to practice near family or an immigrant community.5
  • PSLF can fit, partially. For those who train and practice in hospital/academic/nonprofit (501(c)(3)) settings during the long training and any employed years, 10 years of qualifying payments is plausible across a ~6-year post-med-school training tail plus early attending years, though private-practice retina (the higher-paying endgame) generally is not PSLF-eligible. (Ground it honestly: most physicians carry ~$200k+ in debt; PSLF is real but paperwork-heavy and doesn't fit the private-practice path.)

Risks to name honestly:

  • The gate is the whole story, and it's a double gate. You must first win a spot in ophthalmology, one of the most competitive residencies in medicine, matched through the separate, earlier SF Match where DO seniors match at ~34% and IMG seniors essentially don't, and then win a selective retina fellowship that demonstrably favors US-MD graduates of top-ranked residencies with research and strong surgical numbers.714 For FLI students without built-in mentorship, this is a field you must target very early and deliberately, since home-program exposure, research, and aligned letters matter enormously, and it is not a path you can "back into" late. Weigh the DO/IMG odds soberly.
  • The longest runway. ~14 years from the start of college, with two more fellowship years of trainee pay before attending income, a real cost if you need to start earning and paying down debt fast (though the eventual pay is high enough that the delayed-earning math usually works out if you get there).
  • The pay premium isn't guaranteed forever. Retina's outsized income leans partly on anti-VEGF reimbursement and buy-and-bill drug economics and on ownership, both of which are exposed to policy change and PE consolidation. Don't bank a specific number a decade out.
  • Ownership is the wealth lever, and it may narrow. Like the rest of ophthalmology, private-equity consolidation (retina groups have been major PE roll-up platforms) can erode the independent-ownership path that makes the economics special; an employed/bought-out retina surgeon captures the salary but not the equity upside.

Bottom line for FLI: retina is the highest-earning, most craft-intensive corner of ophthalmology, with genuine ownership-driven wealth potential and unshakeable demand, but it hides behind a double selection gauntlet (competitive residency, then competitive fellowship) that's especially steep for DO and immigrant-graduate students, plus the longest training runway in the field and real reimbursement/ownership uncertainty. Worth targeting early and deliberately if the craft genuinely pulls you and ophthalmology is reachable, and not a field to bank on late. Shadow a busy retina practice, an OR day and a full injection clinic, before you commit, and ask any prospective group exactly how call and the partnership track are structured.

Sub-subspecialties & fellowships

There is nothing formal past surgical retina. No sub-subspecialty fellowship, and no separate board to sit, since retina competence is attested by fellowship completion rather than an ABMS exam.68 The fork that shapes the career happens on the way in, not after.23

  • Surgical retina, the 2-year fellowship. Vitrectomy and buckle work alongside the full medical and injection side. This is the route with the operating room, the surgical call, and the ownership economics the field is known for.
  • Medical retina, commonly 1 year. The same retinal diseases managed through imaging, laser and injections, without intraocular surgery. It suits people who want the diagnostic craft and the clinic without the OR, the longer runway, or the surgical call.
  • Everything else is a practice lean, not a credential. Within surgical retina people build reputations around particular case mixes, but those are built on referral patterns and volume rather than on another year or another certificate.

Fun facts

  • Anti-VEGF injections transformed the field twice over. Before ~2005, wet AMD usually meant progressive central-vision loss; anti-VEGF drugs (starting with the off-label bevacizumab and on-label ranibizumab era) turned it into a treatable disease, and made the intravitreal injection the single most common procedure in a modern retina clinic.
  • Retina is the highest-earning ophthalmology subspecialty (~$699k avg, Physician Side Gigs), and much of that premium comes from injection and surgical volume and drug economics rather than the title.
  • A vitrectomy is done through ports the width of a large needle (25- or 27-gauge, sutureless), and the surgeon removes the eye's vitreous gel and works on tissue microns thick under a microscope.
  • The macula is on a clock too. A "macula-on" retinal detachment (central vision still attached) is a surgical emergency to operate before the macula lifts, one of ophthalmology's few true same-day surgical calls.
  • Retina is the longest standard ophthalmology fellowship at 2 years, and the one where fellowship completion rather than a board exam credentials the subspecialist. Unlike most of medicine, ophthalmology retina has no separate ABMS certificate.
  • "Buy-and-bill," where retina practices purchase costly anti-VEGF drugs and bill Medicare for them, is a large part of why ophthalmology ranked second of all specialties in Medicare Part B payments in CY2021 and why two anti-VEGF drugs accounted for roughly 12% of the entire Part B budget on 2015 data. Drug-pricing policy therefore looms over the field's economics in a way it does not for most of medicine.1112

Sources

Footnotes

  1. Retina/ophthalmology overview, procedures, lifestyle, longevity, competitiveness framing, and FLI synthesis — kept consistent with the ophthalmology profile on this site, which carries the underlying sources (Medscape lifestyle and mental-health reports, SalaryDr, AAO, SF Match and AUPO, and the subspecialty pay ordering with retina highest). 2026. SalaryDr does not publish a panel size for the page cited here (its blog and career-guide pages omit the n that its per-specialty pages carry), so the panel-size caveat this site attaches to a self-selected panel cannot be quantified for this figure. Treat it as a self-selected panel of unknown size. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15

  2. Eyes On Eyecare — "The Ultimate Guide to Retina Fellowship for Ophthalmologists": surgical retina = 2-year fellowship vs medical retina ~1 year; SF Match Central Application Service; ~350–500 primary surgical cases; PPV/scleral buckle/membrane peel; intravitreal injection as most common in-office procedure; ~160 positions/123 filled (2019). https://eyesoneyecare.com/resources/ultimate-guide-retina-fellowship-ophthalmologists/ (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11

  3. Student Doctor Network, "Retina lifestyle update? surgical vs medical?" — paraphrased community sentiment (practicing retina surgeons): private-practice surgical retina "very reasonable," ~40–60 visits/day over ~4 clinic days + ~1 OR day/week, most emergencies during clinic hours, late surgeries only a handful/year (mainly endophthalmitis), weekend post-op checks ~1–2×/month; starting ~$200–300k with partnership step-up; reimbursement and partnership-track transparency as top concerns. This is a forum, and the posts are dated: the thread opened 10 May 2014 and its substantive replies run to 22 October 2016. Read as anecdote, not survey data. https://forums.studentdoctor.net/threads/retina-lifestyle-update-surgical-vs-medical.1070474/ (accessed 2026). Corrected 2026-08-17: this footnote named the forum and the thread but gave only the retrieval year, so the page carried a forum-sourced pay figure without the date of the posts and without the word anecdote, two of the three things this site requires. Both are now present, in the footnote and in the body. The post dates matter more than the label does: the starting-salary range is from 2014–2016 and had been read as current. The claim that established retina practices generate $1.5–2M a year has also been removed. A poster describing their own salary is first-hand testimony about their own life, which is what forums are good for, but a practice's annual revenue is a business fact about an institution, which a forum cannot source. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  4. Physician Side Gigs — Average Ophthalmologist Salary: retina (vitreoretinal) ~$699,000 average, ≈37% above the specialty average and the top subspecialty; ownership/setting splits (group non-PE, PE-backed) and the W-2-vs-owner premium. https://www.physiciansidegigs.com/average-ophthalmologist-salary (2023–24 data, accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  5. Anti-VEGF/injection volume, buy-and-bill economics, and demand tailwinds (aging → AMD, diabetes → retinopathy) — Road to MD synthesis consistent with parent ophthalmology profile and retina practice-economics reporting; buy-and-bill and Medicare Part B drug-margin exposure noted as a policy-sensitive income lever. 2026. ⟳ ↩ ↩2 ↩3 ↩4

  6. Most ophthalmology fellowships, retina among them, are non-ACGME, overseen by the AUPO Fellowship Compliance Committee and matched via SF Match; no separate ABMS retina board (certification remains general ophthalmology). Ophthalmic plastic and reconstructive surgery is the exception on accreditation, with 4 ACGME-accredited programs and 5 fellows in AY2024-25 per ACGME's Data Resource Book, Academic Year 2024-2025 (https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf); there is no such row for retina. Swept 2026-08-17: this note generalized the non-ACGME status to ophthalmology fellowships as a class, which the book's own row refutes. Retina's own status is unaffected, and the body already hedged it correctly as "almost all." See the oculoplastic surgery profile, where the exception belongs. ABMS explored a retina "Area of Focused Practice" designation (application doc dated 2024) but no standard retina board exam exists as of 2026. See the ophthalmology profile on this site for the parent-field version. AUPO FCC Surgical Retina & Vitreous (https://aupofcc.org/fellowship-programs-residentssubspecialties/surgical-retina-and-vitreous); ABMS FPD application (https://www.abms.org/wp-content/uploads/2023/11/abms-fpd-application-retina-revised-february-2024.pdf). 2026. ⟳ ↩ ↩2 ↩3

  7. Burton E, Mishra K, Arsiwala LT, Zafar S, Justin GA, Mruthyunjaya P, Woreta FA. "Applicant Characteristics Associated with Retina Fellowship Match from 2010–2019," Ophthalmology Retina 2022;6(12) — programs ~101→119, filled ~118→123, offered up to ~160 (~37 vacant); independent predictors of matching: US residency (~2.08×), top-10 residency (~1.74×), allopathic MD (~2.39× vs other degrees), each additional interview (~1.28×; matched median ~10 interviews), higher Step 3; US visa status favored in the unadjusted comparison only. PubMed 35772695. https://pubmed.ncbi.nlm.nih.gov/35772695/ (2022). Corrected 2026-08-17: the paper's title spans 2010–2019 but its two datasets do not. The program-and-position counts are drawn from SF Match data for 2014 to 2019; the applicant-characteristics analysis covers match cycles 2010 to 2017. The body previously attributed the 101→119 and 118→123 movements to a 2010–2019 window. The body also listed US visa status alongside US-residency graduation as a strong predictor of matching; it appears in the paper's unadjusted comparison and not among the five predictors that survive the multivariable model. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  8. American Board of Ophthalmology (ABO) — general ophthalmology certification (Written Qualifying Exam + Oral Exam, 10-year certificate); no retina-specific ABMS subspecialty board. See the ophthalmology profile on this site for the parent-field version. ABO (https://abop.org). 2026. ↩ ↩2 ↩3 ↩4

  9. SalaryDr — Retina Ophthalmologist Salary (updated 2026, n≈12, owner-heavy crowdsource — treat as upper/owner-range illustration): median ~$700,000, average ~$628,000, 25th–75th pct ~$508k–$740k; private practice ~$633k vs hospital-employed ~$604k; career satisfaction 4.7/5. Ten of the twelve respondents said they would choose the field again, reported on this page as a count rather than as 83%. Corrected 2026-08-13: this footnote previously said the figure had been removed because no publisher breaks that question out by specialty. That is true of cross-specialty comparison and not of this figure, which is SalaryDr's own panel answering its own question. https://www.salarydr.com/specialty/ophthalmology/retina (accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  10. Marit Health — Retina Ophthalmologist Salary: ~$545k average (broader-sample figure, lower than crowdsource medians). https://www.marithealth.com/o/-/retina-ophthalmologist/salary (accessed 2026). ⟳ On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. ↩

  11. Medicare Part B payments by specialty. CMS, Medicare Part B Physician/Supplier National Data — CY2021 Expenditures and Services by Specialty: ophthalmology $7,348,259,196 in payments on 55,551,300 allowed services, second of all specialties behind internal medicine ($7,834,353,592) and ahead of hematology/oncology, diagnostic radiology and cardiology, against a Part B total of $118,191,557,198. https://www.cms.gov/files/document/cy-2021-expenditures-and-services-specialty.pdf (CY2021 data). ⟳ Added 2026-08-17: "one of the highest-Medicare-billing specialties in all of medicine" was asserted twice on this page, in the compensation section and in Fun facts, with no citation anywhere and no footnote marker on either sentence. It is a specific, ranked, checkable claim about CMS payment data, and it is load-bearing: it is one of three stated reasons retina out-earns comprehensive ophthalmology, it drives the page's argument that the pay premium is policy-exposed, and it appears in the stereotypes and the FLI risks. CMS publishes the table, so the claim is now stated at the rank the table supports. Note the scope: the table reports ophthalmology as a whole, not retina, which is why the second half of the claim now rests on 12. ↩ ↩2

  12. Anti-VEGF share of the Part B budget. American Academy of Ophthalmology, EyeNet, "Medicare Part B Spending and Anti-VEGF Drugs" (1 August 2018), summarizing Berkowitz SR et al. in Ophthalmology Retina: "aflibercept and ranibizumab account for 12% of the Medicare Part B budget," on data through 2015. https://www.aao.org/eyenet/article/medicare-spending-and-anti-vegf-drugs (2018; 2015 data). ⟳ The two drugs in that finding are the ones retina administers, which is the part of the buy-and-bill claim CMS's specialty table cannot show on its own. The 2015 vintage is real and the mix has moved since — biosimilars and a shift toward compounded bevacizumab both cut the per-injection cost — so read 12% as the scale of the exposure rather than as a current figure. ↩ ↩2 ↩3

  13. Ophthalmology burnout/depression baseline. AMA Organizational Biopsy 2025 — nearly 19,000 physician responses across 106 health systems in 38 states — puts Ophthalmology at 25.8% against a 41.9% all-physician average, second-lowest of the rows it names, https://www.ama-assn.org/practice-management/physician-health/these-9-physician-specialties-report-highest-burnout-rates. Corrected 2026-08-17: the dashboard, the body and the wellbeing figure now lead with the AMA row rather than Medscape's 39%. AMA is the instrument this page prefers wherever it publishes a row, because it is free, primary and current. The Medscape rank this page carried — tied with psychiatry for second-lowest of the twenty-six specialties that report covers — was computed in the Medscape frame and is dropped rather than restated. The Medscape readings kept beside it: 2024 at ~39% and 2022 at ~40% burnout with ~10% depression against a ~24% physician average. The 2024 figure is Medscape Physician Burnout & Depression Report 2024 (n=9,226, fielded July–October 2023), which is paywalled and is relayed here through Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty), which puts ophthalmology at 39% against a 49% all-physician average; Advisory Board's write-up (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout) carries no specialty table and does not corroborate the row. See the ophthalmology profile on this site for the parent-field version. Corrected 2026-08-17: the body and the wellbeing figure caption set the 39% against a band of "~47–49% for physicians overall". Nothing on the page sources the 47%; this footnote gives 49% and Healthgrades publishes no baseline of its own. The band is now stated as the single 49% figure the footnote supports. The "second-lowest" ranking is also a tie, which the relayed list shows and the footnote did not. ⟳ ↩ ↩2

  14. Ophthalmology demographics — 28% women practicing and 42.6% of residents; DO seniors match ~34%, IMG seniors ~0% / IMGs ~2–3% of matched; URiM ~15% of 2025 matched. Women in practice: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america . Women in training: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf, for academic year 2024-25. Correction 2026-08-13: this page previously carried ~25–26% of practicing ophthalmologists and a ~40–44% band for residents, in the Quick dashboard and in Who's in the field. The DO, IMG and URiM shares come from the 2025 SF Match General Report rather than NRMP: ophthalmology matches outside the Main Residency Match and carries no row in NRMP, Results and Data: 2026 Main Residency Match, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf . See the ophthalmology profile on this site for the parent-field version. ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  15. Synthesized online sentiment (r/ophthalmology, SDN) — retina as the prestige/highest-paid/most-surgical subspecialty; "injection factory" and "gunner" caricatures; debates over reimbursement/buy-and-bill durability and partnership-track fairness; medical-vs-surgical choice. Paraphrased, no quotes. Road to MD culture briefing, 2026. ↩

  16. Retina Today — "Profile of a Medical Retina Specialist" — the non-surgical retina path (diseases, imaging, laser, injections without the OR/surgical call). https://retinatoday.com/articles/2016-july-aug/profile-of-a-medical-retina-specialist (2016, accessed 2026). ↩

Researched with AI assistance and reviewed by hand. How this site is made